UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 6,980 Shares of Xencor, Inc. (NASDAQ:XNCR)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Xencor, Inc. (NASDAQ:XNCR) by 2.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 332,876 shares of the biopharmaceutical company’s stock after selling 6,980 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.48% of Xencor worth $6,694,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Baillie Gifford & Co. grew its holdings in shares of Xencor by 3.3% in the second quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company’s stock valued at $445,000 after acquiring an additional 744 shares in the last quarter. Louisiana State Employees Retirement System grew its stake in shares of Xencor by 3.0% in the second quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock worth $587,000 after purchasing an additional 900 shares during the last quarter. Diversified Trust Co boosted its position in Xencor by 7.8% during the 2nd quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 1,017 shares in the last quarter. KBC Group NV lifted its holdings in shares of Xencor by 63.5% during the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,213 shares during the last quarter. Finally, WINTON GROUP Ltd lifted its holdings in shares of Xencor by 4.2% during the second quarter. WINTON GROUP Ltd now owns 46,481 shares of the biopharmaceutical company’s stock valued at $880,000 after purchasing an additional 1,883 shares during the last quarter.

Analyst Ratings Changes

XNCR has been the subject of a number of recent analyst reports. Royal Bank of Canada boosted their price objective on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th. Wedbush reiterated an “outperform” rating and issued a $38.00 price target on shares of Xencor in a research note on Thursday, November 7th. JPMorgan Chase & Co. upped their target price on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. BMO Capital Markets reissued an “outperform” rating and issued a $34.00 price objective (up from $32.00) on shares of Xencor in a research report on Friday, November 8th. Finally, Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $20.00 to $30.00 in a research note on Monday, December 2nd. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $36.50.

Insider Activity

In other Xencor news, VP John R. Desjarlais sold 68,684 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the sale, the vice president now directly owns 200,104 shares in the company, valued at $4,698,441.92. This represents a 25.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Alan Bruce Montgomery sold 1,421 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $27.03, for a total transaction of $38,409.63. Following the completion of the sale, the director now owns 9,140 shares in the company, valued at $247,054.20. The trade was a 13.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 136,050 shares of company stock valued at $3,277,609 in the last 90 days. Company insiders own 5.23% of the company’s stock.

Xencor Price Performance

Shares of Xencor stock opened at $25.29 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor, Inc. has a 12 month low of $15.31 and a 12 month high of $27.24. The stock has a market capitalization of $1.77 billion, a P/E ratio of -7.90 and a beta of 0.69. The business has a 50 day simple moving average of $22.73 and a two-hundred day simple moving average of $20.62.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $14.59 million. During the same quarter in the prior year, the company earned ($0.40) EPS. Xencor’s revenue was down 81.9% compared to the same quarter last year. As a group, analysts predict that Xencor, Inc. will post -3.71 EPS for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.